Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021

Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID-19.

Citation:
Douglas AP, Smibert OC, Bajel A, Halliday CL, Lavee O, McMullan B, Blyth CC as part of the Australasian Antifungal Guidelines Steering Commitee. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J. 2021;51 Suppl 7:143-76

Keywords:
Aspergillus; antifungal therapy; diagnosis; haematological malignancy; invasive aspergillosis; stem cell transplant

Abstract:
Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID-19.